Try our Advanced Search for more refined results

Federal Trade Commission et al v. Actavis, Inc.

  1. July 20, 2017

    FTC Balks At Discovery Extension In AndroGel Antitrust Suit

    The Federal Trade Commission objected Wednesday to a group of pharmaceutical companies' request for two more months of expert discovery in an antitrust case alleging they conspired to keep generic competitors for AndroGel off the market, telling a Georgia federal court that a year and a half is enough.

  2. February 08, 2017

    Teva Sub Says It Should Also Be Cut From FTC Androgel Suit

    Teva subsidiary Actavis Holdco Inc. told a Georgia federal court Tuesday the government's dismissal of Par Pharmaceuticals Inc. supports its own bid to exit a lawsuit by the U.S. Federal Trade Commission alleging pharmaceutical companies illegally conspired to delay generic competition for AndroGel.

  3. February 02, 2017

    FTC Asks To Drop Par, Paddock From AndroGel Antitrust Row

    The Federal Trade Commission on Thursday sought to drop Paddock Holdings and Endo subsidiary Par Pharmaceutical from a Georgia federal court case in which it alleges pharmaceutical companies illegally conspired to delay generic competition for AndroGel.

  4. October 17, 2016

    Actavis Holdco Says FTC's AndroGel Antitrust Suit Is Moot

    Newly acquired Teva subsidiary Actavis Holdco asked a Georgia federal court Friday to end claims against it in an FTC lawsuit alleging pharmaceutical companies illegally conspired to delay generic competition for AndroGel, saying it is already operating under an injunction sought by the agency in the case.

  5. January 05, 2016

    FTC Can't See Certain Docs In AbbVie Pay-For-Delay Row

    A Georgia federal judge has allowed AbbVie, Actavis and other drugmakers facing pay-for-delay allegations involving patents for testosterone drug AndroGel to avoid disclosing most of a disputed set of documents to the Federal Trade Commission that they claim are privileged.

  6. July 27, 2015

    FTC Asks AbbVie, Others For Deal Docs In Pay-For-Delay Suit

    The Federal Trade Commission and private plaintiffs suing AbbVie Products LLC and other drugmakers over patent pay-for-delay settlements for testosterone drug AndroGel moved Friday to force the companies to turn over details of their settlement negotiations.

  7. May 11, 2015

    AbbVie Not Allowed To See FTC Docs In Pay-For-Delay Suit

    A Georgia federal judge declined Monday to compel the Federal Trade Commission to turn over nonpublic documents in a pay-for-delay suit the agency is bringing against AbbVie Products LLC and others.

  8. April 07, 2015

    AbbVie Says FTC Can't Fight By Own Rules In Pay-For-Delay

    The Federal Trade Commission should be barred from using studies about the pharmaceutical industry at an upcoming pay-for-delay trial over AndroGel, unless the agency turns over the documents underlying those studies, AbbVie Products LLC and other drugmakers told a Georgia federal judge on Monday.

  9. March 16, 2015

    FTC Says Study Documents Aren't Needed In Actavis Case

    The Federal Trade Commission told a Georgia federal judge Friday it doesn't plan to use its studies about the pharmaceutical industry in a pay-for-delay trial against AbbVie Products LLC and other drugmakers, making the underlying documents irrelevant to the case.

  10. February 17, 2015

    AbbVie Says FTC Withholding Key Docs In Pay-For-Delay Suit

    AbbVie Products LLC has told a Georgia federal court Friday that the Federal Trade Commission should have to turn over the documents underlying its studies about the pharmaceutical industry if it wants to use them at a pay-for-delay trial over AndroGel.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!